Corvus confirms soquelitinib Phase 3 trial for PTCL; initiation Q1 2024

Corvus Pharmaceuticals, Inc.

FDA End-of-Phase meeting completed; trial design confirmed: 150 patients, 1:1 randomization, primary endpoint PFS.
Enrollment of relapsed PTCL patients with ≤3 prior therapies; initiation expected in Q1 2024.
Company to host conference call on Sept 7, 2023 to discuss trial plan and business updates.
Soquelitinib is a selective ITK inhibitor; potential in hematologic cancers, solid tumors, autoimmune diseases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.